BG Medicine (NASDAQ:BGMD) & Signal Genetics (MGEN) Head to Head Analysis

BG Medicine (NASDAQ: BGMD) and Signal Genetics (NASDAQ:MGEN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitabiliy.

Earnings & Valuation

This table compares BG Medicine and Signal Genetics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
BG Medicine	$1.57 million	0.35	-$4.39 million	N/A	N/A
Signal Genetics	$3.02 million	96.33	-$20.05 million	N/A	N/A

BG Medicine has higher revenue, but lower earnings than Signal Genetics.

Insider and Institutional Ownership

16.4% of Signal Genetics shares are held by institutional investors. 44.4% of Signal Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares BG Medicine and Signal Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	-311.03%	N/A	-131.82%
Signal Genetics	-555.68%	-109.13%	-81.59%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BG Medicine and Signal Genetics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	N/A
Signal Genetics	0	0	4	0	3.00

Signal Genetics has a consensus price target of $15.67, suggesting a potential upside of 15.28%. Given Signal Genetics’ higher probable upside, analysts clearly believe Signal Genetics is more favorable than BG Medicine.

Summary

Signal Genetics beats BG Medicine on 7 of the 10 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners’ automated platforms. The Company’s CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

About Signal Genetics

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.